SAB Biotherapeutics, a clinical-stage biopharmaceutical company, went public via a merger with Big Cypress Acquisition, a SPAC, in a c.$325m deal. “SAB met or exceeded our criteria, demonstrating de-risked early development processes, clinical proof-of-concept, therapeutic targets with large unmet needs and what we expect to be manageable Phase 3 trials, high-value indications, and the ability to efficiently put additional capital to work advancing a high potential pipeline," Sam Reich, Big Cypress Acquisition CEO.